Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selumetinib - AstraZeneca

Drug Profile

Selumetinib - AstraZeneca

Alternative Names: AR 00142886; AR 142886 X; ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; MK 5618; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Cincinnati Children's Hospital Medical Center; M. D. Anderson Cancer Center; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Samsung Medical Center; Sheffield Teaching Hospitals NHS Foundation Trust; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Neurofibromatoses; Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioma; Histiocytosis; Neurofibromatoses; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Phase I/II Astrocytoma; Kaposi's sarcoma; Plexiform neurofibroma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Liver cancer; Malignant melanoma; Multiple myeloma; Thyroid cancer

Most Recent Events

  • 26 Sep 2019 Phase-I/II clinical trials in Glioma (In adolescents, In children, Inoperable/Unresectable, Second-line therapy or greater, In adults) in United Kingdom (PO, Tablet) (NCT03326388)
  • 26 Sep 2019 Phase-I/II clinical trials in Glioma (Inoperable/Unresectable, In children, In adolescents, In adults, Second-line therapy or greater) in United Kingdom (PO, Capsule) (NCT03326388)
  • 26 Sep 2019 Phase-I/II clinical trials in Neurofibromatoses (In adolescents, In children, Inoperable/Unresectable, Second-line therapy or greater, In adults) in United Kingdom (PO, Capsule) (NCT03326388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top